{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:31:07Z","timestamp":1773297067771,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejpb.2023.12.002","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T15:34:48Z","timestamp":1702308888000},"page":"118-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Intranasal administration of sertraline ensures sustained brain delivery and antidepressant effect in a mouse model of depression"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6726-5458","authenticated-orcid":false,"given":"Soraia","family":"Silva","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3320-9658","authenticated-orcid":false,"given":"Carla","family":"Fonseca","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-1671","authenticated-orcid":false,"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3854-6549","authenticated-orcid":false,"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.12.002_b0005","series-title":"Depression and Other Common Mental Disorders: Global Health Estimates","author":"Who","year":"2017"},{"key":"10.1016\/j.ejpb.2023.12.002_b0010","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","author":"Santomauro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2023.12.002_b0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/0020764020915212","article-title":"The outbreak of COVID-19 coronavirus and its impact on global mental health","volume":"66","author":"Torales","year":"2020","journal-title":"Int. J. Soc. Psychiatry"},{"key":"10.1016\/j.ejpb.2023.12.002_b0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2014.07.046","article-title":"Faster, better, stronger: towards new antidepressant therapeutic strategies","volume":"753","author":"O'Leary","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.12.002_b0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2015.17.2\/dionescu","article-title":"Pharmacological approaches to the challenge of treatment-resistant depression","volume":"17","author":"Ionescu","year":"2015","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.ejpb.2023.12.002_b0030","first-page":"CD006117","article-title":"Sertraline versus other antidepressive agents for depression","author":"Cipriani","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejpb.2023.12.002_b0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/ph15050565","article-title":"A Focus on Abuse\/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases","volume":"15","author":"Chiappini","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejpb.2023.12.002_b0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejpb.2023.12.002_b0045","first-page":"12","article-title":"Pharmacology of Rapid-Onset Antidepressant Treatment Strategies","volume":"62","author":"Blier","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejpb.2023.12.002_b0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0165-0327(99)00120-2","article-title":"Efficacy of intravenous citalopram compared with oral citalopram for severe depression: Safety and efficacy data from a double-blind, double-dummy trial","volume":"58","author":"Guelfi","year":"2000","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejpb.2023.12.002_b0055","first-page":"203","article-title":"A double-blind double-dummy study of citalopram comparing infusion versus oral administration","volume":"49","author":"Baumann","year":"1998","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.ejpb.2023.12.002_b0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00406-002-0363-8","article-title":"Intravenous antidepressant treatment: focus on citalopram","volume":"252","author":"Kasper","year":"2002","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ejpb.2023.12.002_b0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.brainres.2015.07.005","article-title":"Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders","volume":"1628","author":"Qosa","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.ejpb.2023.12.002_b0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade","volume":"370","author":"Chen","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejpb.2023.12.002_b0075","doi-asserted-by":"crossref","first-page":"e56525","DOI":"10.1371\/journal.pone.0056525","article-title":"Effects of sertraline and fluoxetine on p-glycoprotein at barrier sites: in vivo and in vitro approaches","volume":"8","author":"Kapoor","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.12.002_b0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpsychires.2015.11.010","article-title":"Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study","volume":"73","author":"Breitenstein","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejpb.2023.12.002_b0085","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jphp.13100","article-title":"In-vitro and in situ assessment of the efflux of five antidepressants by breast cancer resistance protein","volume":"71","author":"Feng","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.12.002_b0090","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003088-200241150-00002","article-title":"Clinical Pharmacokinetics of Sertraline","volume":"41","author":"DeVane","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2023.12.002_b0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cbi.2015.10.006","article-title":"Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies","volume":"242","author":"Shahlaei","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejpb.2023.12.002_b0100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jat\/bkt014","article-title":"Analysis of sertraline in postmortem fluids and tissues in 11 aviation accident victims","volume":"37","author":"Lewis","year":"2013","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.ejpb.2023.12.002_b0105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1752-1947-3-126","article-title":"Pulmonary fibrosis associated with psychotropic drug therapy: a case report","volume":"3","author":"Thornton","year":"2009","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.ejpb.2023.12.002_b0110","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2147\/CIA.S144263","article-title":"The relationship of SSRI and SNRI usage with interstitial lung disease and bronchiectasis in an elderly population: a case-control study","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.ejpb.2023.12.002_b0115","doi-asserted-by":"crossref","first-page":"omab014","DOI":"10.1093\/omcr\/omab014","article-title":"Sertraline as a rare cause of interstitial lung disease","volume":"2021","author":"Lepore","year":"2021","journal-title":"Oxf. Med. Case Res."},{"key":"10.1016\/j.ejpb.2023.12.002_b0120","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.drudis.2019.06.001","article-title":"Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges","volume":"24","author":"Vitorino","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2023.12.002_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.751321","article-title":"Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro\/In Vivo Evaluation","volume":"12","author":"Silva","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.12.002_b0130","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/10717544.2017.1357148","article-title":"Agomelatine-based in situ gels for brain targeting via the nasal route: statistical optimization, in vitro, and in vivo evaluation","volume":"24","author":"Fatouh","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2023.12.002_b0135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000087097","article-title":"Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS","volume":"52","author":"Willner","year":"2005","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.ejpb.2023.12.002_b0140","first-page":"e52434","article-title":"Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice","author":"Seibenhener","year":"2015","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejpb.2023.12.002_b0145","unstructured":"ICH, Bioanalytical Method Validation, ICH Harmonised Guideline. (Endorsed on 26 February 2019)."},{"key":"10.1016\/j.ejpb.2023.12.002_b0150","unstructured":"C. Fonseca, E. M., A. Camins, R. Ferreira, J. Bicker, R. Barbosa, A. Fortuna, New HPLC technology for monitoring neurotransmitters in the brain: a pre-clinical approach for neurological disorders [Abstract]. In: International Multi-Brain Barcelona Congress - Healthy, Pathological and Artificial Brain, 2022. Available at: https:\/\/www.ub.edu\/UBneuroCongress2022\/wp-content\/uploads\/2022\/11\/abstract-book_multibrain.pdf. Accessed at 21.07.2023."},{"key":"10.1016\/j.ejpb.2023.12.002_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120161","article-title":"A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration","volume":"593","author":"Gon\u00e7alves","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.002_b0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11095-020-02786-z","article-title":"Pre-Clinical Assessment of the Nose-to-Brain Delivery of Zonisamide After Intranasal Administration","volume":"37","author":"Goncalves","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.12.002_b0165","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijpharm.2019.04.047","article-title":"Nose-to-brain delivery of levetiracetam after intranasal administration to mice","volume":"564","author":"Gon\u00e7alves","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.002_b0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijpharm.2015.05.021","article-title":"Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice","volume":"490","author":"Serralheiro","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.12.002_b0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejps.2014.04.019","article-title":"Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting","volume":"60","author":"Serralheiro","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.12.002_b0180","first-page":"e2021027","article-title":"Sertraline-Associated Interstitial Lung Disease: A case series and Literature Review","volume":"38","author":"Izhakian","year":"2021","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.ejpb.2023.12.002_b0185","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejpb.2020.04.011","article-title":"QbD-driven development of intranasal lipid nanoparticles for depression treatment","volume":"153","author":"Vitorino","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.12.002_b0190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.intimp.2018.12.011","article-title":"Sertraline ameliorates inflammation in CUMS mice and inhibits TNF-alpha-induced inflammation in microglia cells","volume":"67","author":"Lu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejpb.2023.12.002_b0195","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/JPR.S176857","article-title":"Melatonin is a biomarker of circadian dysregulation and is correlated with major depression and fibromyalgia symptom severity","volume":"12","author":"Caumo","year":"2019","journal-title":"J. Pain Res."},{"key":"10.1016\/j.ejpb.2023.12.002_b0200","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/1570159X12999140619122914","article-title":"Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks","volume":"12","author":"Gahr","year":"2014","journal-title":"Curr. Neuropharmacol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123003260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123003260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:54:36Z","timestamp":1760547276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123003260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":40,"alternative-id":["S0939641123003260"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.002","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal administration of sertraline ensures sustained brain delivery and antidepressant effect in a mouse model of depression","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}